Cue Biopharma (CUE) Total Non-Current Liabilities (2018 - 2021)

Cue Biopharma has disclosed Total Non-Current Liabilities across 4 years of filings, most recently posting $17.9 million for Q4 2021.

• Total Non-Current Liabilities for Q4 2021 came in at $17.9 million, down 4.15% year-over-year; the trailing twelve-month figure through Dec 2021 was $17.9 million (down 4.15% YoY), and the FY2021 annual result was $17.9 million, down 4.15% from the prior year.
• Total Non-Current Liabilities came in at $17.9 million for Q4 2021 at Cue Biopharma, up from $16.7 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $18.7 million in Q4 2020 to a low of $3.0 million in Q2 2018.
• The 4-year median for Total Non-Current Liabilities is $15.1 million (2019), against an average of $13.2 million.
• Across the five-year window, Total Non-Current Liabilities jumped 408.1% in 2019 and slipped 20.85% in 2020, its largest moves.
• Cue Biopharma's Total Non-Current Liabilities stood at $6.2 million in 2018, then surged by 109.16% to $13.0 million in 2019, then surged by 43.69% to $18.7 million in 2020, then declined by 4.15% to $17.9 million in 2021.
• The last three Total Non-Current Liabilities figures came in at $17.9 million (Q4 2021), $16.7 million (Q2 2021), and $17.7 million (Q1 2021), per Business Quant data.